News & Updates

The use of tirzepatide delivers a better safety profile when compared to other glucagon-like peptide-1 receptor agonists (GLP-1RAs), as shown by the lower risk of gastrointestinal (GI) side effects associated with its use, reports a real-world study presented at DDW 2025.

Treatment with glucagon-like peptide-1 receptor agonists (GLP-1RAs), as opposed to insulin or metformin, provides a protective benefit against the development of gastrointestinal cancers, as shown in a study presented at DDW 2025.

General and central obesity are both significant risk factors for the development of irritable bowel syndrome (IBS), suggests a study.

An individual’s gut microbiota profile appears to be associated with chronic heart failure (CHF) risk factors, potentially mediated by microbial metabolites, results of a recent study have shown.

Patients with acute pancreatis who are residing in areas with higher Social Vulnerability Index (SVI) ranks are more likely to withdraw from alcohol use, according to a study.

Survival outcomes do not differ between patients with locally advanced rectal cancer treated with mandatory total mesorectal excision (TME) and those on selective watch-and-wait (WW) strategies following total neoadjuvant therapy (TNT), reports a study.

Treatment with linaclotide led to significantly improved symptoms of incomplete bowel evacuation and straining in paediatric patients aged 6–17 years with functional constipation, according to a phase III study presented at DDW 2025.

Exposure to angiotensin-converting enzyme inhibitors (ACE-I) and angiotensin receptor blockers (ARB) may prevent mortality among patients with cirrhosis, a study has shown.

Treatment with tenofovir alafenamide (TAF) is generally safe and effective for the prevention of hepatitis B virus (HBV) mother-to-child transmission (MTCT), reports a study, noting that the expected 8-week prenatal duration is feasible.